New DD - BioAdaptives Announced Intention to Spin off Its Livestock Impact Division. This division is much bigger than we think. https://www.livestockimpact.com/ This information was post on https://www.livestockimpact.com/pages/primicell-study. Under clinical studie my guess a retired Harvard Medical School professor that is our CEO and Medical Doctor from China with a PhD in toxicology is Dr. Yaguang Liu. The third member is a Medical Doctor from Saint Petersburg, Russia. For now I don't have a detailed description of her professional background yet.
THE SCIENCE—BACKGROUND & STUDIES—BEHIND PRIMICELL® AND ITS DERIVATIVES
This project was initiated over seven years ago with the objective of development. It holds significant importance as the Protocols for a Human Clinical trial were formulated and received approval from an IRB. PRIMICELL® has undergone testing in various countries and has proven its effectiveness on humans, horses, dogs, mice, and farm animals. If the company successfully finds sponsor PRIMICELL® for the IPO-SPIN-OFF of Its Livestock Impact division, we could be in for an extraordinary journey.
Our advisory team consists of 3 highly accomplished physicians with impressive CVs and major clinical research experience with global companies. They are: A retired Harvard Medical School professor, who over 20 years ago, sold his ear nose and throat practice and began a new career developing effective human clinical trials. The next member is a Medical Doctor from China with a PhD in toxicology. He is an associate professor University of Albany. The third member is a Medical Doctor from Saint Petersburg, Russia. She has worked for over 20 years in the pharmaceutical industry and human clinical trials.